Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Multicomponent Intervention Study- Blood Donors With High Cholesterol

Implementing a Multicomponent Intervention to Treat Blood Donors With Familial Hypercholesterolemia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).

Who May Be Eligible (Plain English)

Who May Qualify: - Blood donors from Carter BloodCare with high cholesterol meeting MEDPED FH criteria - Age 18 to 75 years Who Should NOT Join This Trial: - Currently taking medication to lower cholesterol - Taking any medication that can interact with statins - Pregnancy - Identified secondary cause of elevated lipids - Chronic liver disease or significantly elevated liver function tests (\> 3 times upper limit) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Blood donors from Carter BloodCare with high cholesterol meeting MEDPED FH criteria * Age 18 to 75 years Exclusion Criteria: * Currently taking medication to lower cholesterol * Taking any medication that can interact with statins * Pregnancy * Identified secondary cause of elevated lipids * Chronic liver disease or significantly elevated liver function tests (\> 3 times upper limit)

Treatments Being Tested

BEHAVIORAL

Implementation Strategy Bundle

Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.

OTHER

Usual care notification

Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.

Locations (1)

UT Southwestern Medical Center
Dallas, Texas, United States